Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)a and allows fatty acids to be used as fuel. However, the role of PPARa in CLL is unclear. PPARa was found to be expressed by circulating CLL cells and highly associated with advanced stage disease. Consistent with this observation, palmitate oxidation rates in circulating CLL cells were similar to more conventional fat-burning cells such as muscle. Transgenic expression of PPARa in CD5
INTRODUCTION
Despite the promise of new agents, 1 chronic lymphocytic leukemia (CLL) remains a fatal disease, especially once patients have relapsed from first-line treatment with fludarabinecontaining regimens. 2 There is a need to identify new agents with therapeutic activity against CLL for such patients.
Over 10 years ago, expression of lipoprotein lipase (LPL) was found to be associated with CLL cells that exhibit aggressive clinical behavior. 3 LPL cleaves fatty acids from circulating lipoproteins that can be used as fuel by nearby cells. 4 Accordingly, LPL expression implied that CLL cells may have a pathological dependence on fatty acid oxidation, in contrast to acute leukemias that depend on the Warburg effect and glycolysis to obtain their energy. 5 Aberrant intermediary metabolism as a target for cancer treatment is currently of great interest. 6 However, there are relatively few clinically relevant fatty acid oxidation inhibitors. 7 Peroxisome proliferator activated receptor (PPAR)a is a central regulator of fatty acid oxidation 8 and is activated by products of LPL. 4 PPARa antagonists might then be a therapeutic approach for CLL in a similar fashion as antagonists of estrogen and androgen nuclear receptors are used for breast and prostate cancer. 9 MK886 was developed as a nanomolar leukotriene inhibitor in the 1990's 10 but subsequently shown to be a PPARa inhibitor at low micromolar concentrations. 11 Because of the potential clinical relevance of MK886, the studies in this paper were initiated to investigate PPARa expression in CLL and the therapeutic potential of MK886.
MATERIALS AND METHODS

Tumor cells
Heparinized blood was obtained from consenting CLL patients, diagnosed by standard criteria 12 and untreated for at least 3 months. Patient characteristics are listed in Table 1 . Protocols were approved by the Sunnybrook Ethics Review Board.
CLL and peripheral blood mononuclear cells were collected and isolated immediately as before. 13 Centrifuged plasma was stored at À 20 1C. CLL splenocytes were obtained from consenting patients undergoing splenectomies.
STAT1, STAT3, phospho-(Tyr
701
)STAT1 and phospho- (Tyr 705 )STAT3 antibodies were from Cell Signaling Technology (Beverly, MA, USA), as were secondary horseradish peroxidase-conjugated antirabbit and antimouse antibodies (Cat. Nos. 7074 and 7076, respectively). PPARa antibodies (ab2779) were from Abcam (Toronto, ON, Canada).
Cell culture and activation Unless otherwise specified, purified CLL cells (1.5 Â 10 6 cells/ml) were cultured in serum-free AIM-V medium plus 2-ME (Sigma) (5 Â 10 À 5 M) in 6-or 24-well plates (BD Labware, Franklin Lakes, NJ, USA) at 37 1C in 5% CO 2 for the times indicated in the figure legends. Resiquimod IL-2, and phorbol dibutyrate were used at 1 mg/ml, 500 U/ml, or 10 ng/ml, respectively, as previously described. 16 Lipid-rich bovine serum albumin (Albumax) was from Invitrogen. Mixed lymphocyte responses were performed as previously described. 17 
Hypoxic treatment
Cells were cultured at 1 Â 10 6 cells/ml in a modular incubator chamber (Billups-Rothenberg Inc., Del Mar, CA, USA) flushed with hypoxic gas (0.5% O 2 , 5% CO 2 , 94.5% N 2 ). Anaerobic conditions were confirmed by using an O 2 gas sensor, which read the O 2 content in the chamber to be B0%.
Immunophenotyping
Flow cytometric analysis and detection of membrane TNFa (mTNF) were performed as before. 17 
Western blots
Immunoblotting was performed as before. 17 Band intensities on the gel were quantified using the GeneTools Analysis Software version 4.00 from Syngene Genius 2 Bioimager (Syngene, Frederick, MD, USA). A protein extract from one patient not listed in Table 1 was aliquoted at 50 mg and loaded in each SDS-polyacrylamide gel electrophoresis gel as an internal control across different gels. The densitometry value for each patient sample was then normalized against b-actin and then normalized again to the number for the reference standard to obtain the PPARa intensity reported in Table 1 .
Real-time PCR amplification
Isolation of total RNA and synthesis of complementary DNA were performed as before. 17 The following primers were used for amplification: Normal range is 0.6-2.3 mg/ml.
e Including alkylator-, fludarabine-, high-dose glucocorticoid-, and/or antibody-based treatments, splenectomy, and radiation.
f Based on the densitometry measurements of the immunoblots in Figure 1c Normalized to the control sample in the first lane as described in the Materials and methods. analysis of amplification products was done by cooling the samples to 4 1C and then increasing the temperature to 95 1C at 0.2 1C/s. Fast loss of fluorescence is observed uniquely at the denaturing/melting temperature of the amplified DNA fragment. Standard curves were generated with serial 10-fold dilutions of complementary DNAs made with the same primers as for real-time PCR.
Glucose and fatty acid oxidation measurements Glucose in culture supernatants was measured with an Accu-Chek Aviva blood glucose meter and test strips (Roche Diagnostics, Laval, Quebec, Canada) according to the manufacturer's instructions.
Palmitate oxidation was measured as before with minor modifications. 18 Palmitate was conjugated with fatty acid-free bovine serum albumin to generate a stock solution of 25% (w/v) bovine serum albumin and 6 mM fatty acid in serum-free medium. C)palmitic acid and nonlabeled palmitate (100 mM). Dishes were sealed with parafilm and a piece of Whatman paper was taped to the inside. After 1 h, the paper was wetted with 100 ml of phenylethylamine-methanol (1:1) to trap CO 2 . Subsequently, 200 ml of H 2 SO 4 (4 M) was added to the cells, which were then incubated for an additional 1 h at 37 1C. Finally, the papers were transferred to scintillation vials for radioactivity counting. Results were normalized to the amount of protein in the samples and experiments were performed in triplicate.
CLL xenograft model NOD-SCIDg c null mice (8-13 weeks old) were irradiated (245 rads) and injected intraperitoneally (ip) with 2.5 Â 10 8 thawed CLL splenocytes followed by biweekly ip injections of 700 ml of plasma pooled from 8-10 patients with high white blood cell counts. CLL engraftment in spleens and peritoneal cavities was assessed by flow cytometry, as before. 14 
Pharmacokinetics
BALB/c mice, purchased from The Jackson Laboratory (Bar Harbor ME, USA), were fasted for 15-24 h before injecting MK866 (10 mg/kg ip) and killed by CO 2 inhalation at 2 and 18 h post dose (nX2 per time point). Blood (B300 ml) was collected via cardiac puncture into EDTA-containing tubes and centrifuged at 1450 Â g for 10 min. Plasma was removed and stored frozen ( À 80 1C) before analysis of MK886 content by liquid chromatography-mass spectrometry as previously described, 15 with known amounts of MK886 added to thawed mouse plasma to yield a concentration range from 1-20 mM and provide a calibration curve.
CD5
þ PPARA hi daudi cells
The PPARa CMV Expression Vector (cat.no.ME0001) was purchased from Affimetrix Inc. (Santa Clara, CA, USA). Full-length PPARa cDNA (B1.4 kb) was excised with BamHI and NotI and subcloned into the BamHI and NotI site of the pcDNA3 expression vector. DH5 a E. coli were transformed with PcDNA3-PPARa. Plasmid DNA was extracted with a Qiagen max preparation kit (Qiagen Sciences, Germantown, MD, USA) and transfected into CD5 þ Daudi cells 19, 20 using Lipofectamine 2000 (Invitrogen). PPARa and control vector-transfected cells were selected with 800 mg/ml of Neomycin (G418) (Invitrogen) beginning 48 h after the transfection. Transfected cells that survived selection were cloned by limiting dilution. Daudi cells were grown in RPMI with 5% FCS.
Statistical analysis
The Student t-test was used to determine P-values for differences between sample means.
RESULTS
PPARa is expressed by circulating CLL cells
To determine if PPARa was expressed by CLL cells, PPARA mRNA was measured by real-time PCR in circulating CLL cells from two patients. PPARA was present in these cells at around threefold higher levels than in peripheral blood mononuclear cells from a normal donor (Figure 1a , top panel). In contrast, PPARg, another member of the PPAR family that regulates lipid storage in monocytes and adipocytes, 8 was not expressed by CLL cells (Figure 1a , bottom panel). PPARa is an important regulator of fatty acid oxidation and, as predicted by the PPARA message levels, CLL cells oxidized radio-labeled palmitate more than normal B cells ( Figure 1b ).
PPARa protein levels were then measured in freshly isolated CLL cells from 26 patients (Figure 1c ) whose clinical characteristics are described in Table 1 . Variable levels of PPARa were found in most samples but were low (defined as normalized densitometric intensity o0.5) in a small group of patients (Pt. 2, 5, 18 and 19). Interestingly, these patients tended to have features associated with low-risk disease such as clinical Rai stage 0-II, low b2m plasma levels, low CD38 expression on tumor cells, low white blood cell counts, no indications for treatment and no high-risk cytogenetic features (that is, trisomy 12, 17p or 11q deletions) (Figure 1d ). Only the associations with clinical stage and white blood cell count were highly significant in this small patient cohort but the results suggested that PPARa is associated with more aggressive disease and may be a therapeutic target in the patients that are in need of new treatment strategies.
PPARa expression is associated with increased IL10 and resistance to cytotoxic stressors Clinically aggressive CLL cells produce an immunosuppressive state in patients that is characterized by high levels of circulating IL10. 21 Such cells are also able to survive in harsh environmental conditions caused by hypoxia, lack of nutrients or exposure to chemotherapeutic drugs. To determine if PPARa might be associated with these pathological features, a human PPARa transgene was expressed in a model CLL cell-line that we have developed. 19, 20 Most B cell-lines, even if derived originally from CLL patients, do not express CD5, a defining marker of CLL. 22 They also become dependent on aerobic glycolysis and downregulate PPARa expression after prolonged in vitro culture. 23 Accordingly, they may not faithfully represent primary CLL cells (Figure 1 ).
Daudi is a CD5
À cell line from a Burkitt's lymphoma patient that acquires many properties of proliferating CLL cells, including IL10 production, following transduction with a retrovirus that expresses human CD5. The cell-lines were then exposed to different concentrations of fludarabine, vincristine (a microtubule inhibitor that is considered the most toxic drug to CLL cells in vitro), 17 or peruvoside (a Na-KATPase inhibitor with potent cytotoxicity against CLL cells). 25 Again, PPARA hi cells were less sensitive to these drugs than control cells with low PPARa expression (Figure 2f ). These findings suggest that increased expression of PPARa is associated with gene programs that mediate an immunosuppressive phenotype and resistance to environmental and chemotherapeutic stressors. Downregulation of PPARA in CLL cells is associated with immunogenic death CLL cells originate in proliferation centers, 26 which must be eliminated to cure CLL. We previously developed an in vitro model to learn how to kill tumor cells in proliferation centers. 16 IL-2 and the toll-like receptor-7/8 agonist Resiquimod are used as representative signals in proliferation centers 27 to activate NFkB and cause CLL cells to proliferate and acquire an immunosuppressive phenotype marked by expression of IL-10 and pSTAT3 and inability to stimulate type 1 T cells. These cells, called 2S cells (Figure 3a) , recapitulate some of the behavior of CLL cells in proliferation centers. 28 When 2S cells are treated with phorbol dibutyrate, they come out of cycle, turn off IL-10 and pSTAT3, produce inflammatory cytokines and costimulatory molecules such as TNFa, CD83, CD54 and CD80, and either die or can stimulate tumor-reactive T cells to kill them (Figure 3a) . 16 The behavior of these cells, called P2S cells, is consistent with immunogenic death.
17,29
PPARA expression patterns were examined in the immunosuppressive 2S or immunogenic P2S differentiation pathways (Figure 3b ). PPARA mRNA levels had decreased 24 h after activation but were lower in P2S cells compared to 2S cells (Figure 3b, top panel) . PPARa regulates fatty acid oxidation by controlling the expression of proteins such as UCP2, which facilitates fatty acid transport into mitochondria. 8 Consistent with the expression pattern of PPARA, UCP2 levels ( Figure 3b Table 1 . Protein extracts were frozen immediately and PPARa levels were measured by immunoblotting, with b-actin used as a loading control. The densitometric reading for each sample was normalized to the corresponding b-actin intensity and then to the reading for 'con' in lane 1, which was a common sample included to allow for comparison of blots. (d) Patients were grouped into low PPARa-expression (o0.5) (4 patients) and medium-high expression (40.5) (22 patients) on the basis of the densitometry readings. Rai stage, b2m levels (mg/ml), CD38 levels (%), high-risk fluorescence in situ hybridization abnormalities (% of available results Â 10), number of treatments and circulating white blood cells counts ( Â 10 7 cells/ml) for each group were obtained from the clinical records (Table 1 ). The average and s.e. for each property are plotted. *Po0.001; **Po0.05.
P2S cells, and intermediate in immunosuppressive 2S cells.
Glucose levels in culture supernatants after 48 h showed similar patterns (Figure 3c, top panel) , suggesting that glucose usage increased during immunogenic death.
The temporal course of PPARA, UCP2, TNFA and IL10 expression (Figure 3d ) revealed that PPARA and UCP2 mRNA levels began to decrease almost immediately following stimulation but the decrease was always more profound in P2S cells compared with 2S cells (Figure 3d , lower panels). TNFA mRNA peaked within a few hours of initial activation and fell to lower levels within 10 h but was much higher in P2S cells compared with 2S cells (Figure 3d , left upper panel). IL-10 mRNA began to fall in P2S cells after 4 h and was very low after 24 h. In contrast, IL-10 mRNA continued to increase in 2S cells (Figure 3d, right upper panel) . Taken together, these results suggested that immunogenic death was coupled to a greater downregulation of PPARa. death (Figure 3) is that a PPARa antagonist such as MK886 might have therapeutic activity in CLL. To address this, purified CLL cells from five different patients were cultured in varying concentrations of MK886. Viable cells were measured 2 days later by flow cytometry. MK886 was found to be toxic to CLL cells in the range of 10 mM (Figure 4a) where it is reported to inhibit PPARa.
11
MK886 confers an immunogenic-death phenotype on proliferating CLL cells The effects of MK886 on proliferating 2S cells were then studied. MK886 inhibited the proliferation of 2S cells (Figure 4b ), increased their production of TNFa, and decreased their expression of IL-10 ( Figure 4c ). Increased TNFa and decreased IL-10 were reflected in decreased pSTAT3 levels (Figure 4d) , characteristic of P2S cells undergoing immunogenic death (Figure 3a) .
Surface expression of the adhesion molecule CD54 increased when CLL cells were activated with IL-2 and Resiquimod in the presence of MK886 (Figure 4e ). CD54 is a surrogate marker for immunogenic antigen-presenting cells 30 and 2S CLL cells treated with MK886 were better able to stimulate proliferation of normal T cells in allogeneic mixed lymphocyte responses (Figure 4f ). MK886 has PPARa-independent activities, including inhibition of 5-lipoxygenase activating protein, which is involved in leukotriene synthesis. 11 To address the issue of possible offtarget effects of MK886, similar experiments were carried out with AM103, a 5-lipoxygenase activating protein inhibitor with a different molecular structure than MK886, 15 and AA861, a 5-lipoxygenase inhibitor. Neither AM301 or AA861 were toxic to CLL cells (see below) or increased their immunogenic properties (not shown), consistent with the effects of MK886 being independent of leukotriene inhibition.
MK886 clears CLL cells in vivo A pharmacokinetic study was carried out to determine if MK886 levels necessary to inhibit PPARa could be achieved in mice in vivo. Plasma concentrations of B7 mM were present 2 h after a single ip injection of MK886 (10 mg/kg) but the drug was essentially cleared from the circulation by 18 h (Figure 5a ). On the basis of these findings, the ability of MK886 to clear CLL cells from immunodeficient mice was studied using daily ip injections of 5-20 mg/kg of MK886. This xenograft CLL model involves transferring spleen cells from patients who have undergone therapeutic splenectomies into NOD-SCIDg c null mice along with injections of plasma from CLL patients to provide additional support for tumor engraftment. 14 An advantage of this model for drug development is that many mice with identical human disease can be generated due to the large numbers of tumor cells in diseased spleens. In a separate experiment, xenografted mice were treated with AM103 15 to determine if the antitumor activity of MK886 in vivo might be due to its inhibitory effects on leukotrienes. MK886 again cleared CLL cells, while AM103 had little effect (Figure 5d ), suggesting the antitumor effects of MK886 were more consistent with its nuclear receptor antagonist activity than inhibition of bioactive lipid production. MK886 was more toxic than AM103 or DMSO, as indicated by mild weight loss after a week of injections (Figure 5e ), but this toxicity was not severe at doses associated with antitumor activity.
DISCUSSION
The studies reported here provide some new information about CLL biology. PPARa expression appears to be associated with more aggressive forms of CLL although larger studies are needed to confirm this observation (Figure 1) . CLL may then be more dependent on PPARa-regulated fatty acid oxidation (Figure 1 ) than aggressive lymphomas and acute leukemias, which employ aerobic glycolysis as a metabolic strategy. 24 This use of fatty acid oxidation may explain some of the pathological features of CLL cells such as inexorable proliferation in the absence of high glucose uptake. 31 Fatty acid oxidation rates in CLL cells can reach levels of more traditional fat-burning cells such as myocytes 18 ( Figure 1b) . Unlike myocytes or hepatocytes, 32 PPARA does not exhibit a significant diurnal rhythm in CLL cells (Supplementary Figure 1) , suggesting their dependence on fatty acid oxidation is not related to diet. Perhaps PPARa expression in CLL cells reflects an origin in B1 B cells, 26 which characteristically express high levels of this nuclear receptor. 33 Fatty acid oxidation is also the metabolic strategy of regulatory T cells and memory cells 34 that receive chronic signals through their T cell receptors. CLL cells are also thought to be driven by continuous antigenic-signaling, 26 which may similarly cause them to acquire a dependence on fatty acid oxidation.
Fatty acid oxidation has been linked to drug-resistance of cancer cells. 7, 35 The mechanisms are not clear but may be related to the ability of UCP2 (Figure 3 ) to reduce oxidative stress 35 or efficient generation of energy to repair cell damage caused by cytotoxic drugs. PPARa also has anti-inflammatory properties 8 and, as shown in Figure 2 , can mediate the expression of immunosuppressive factors such as IL-10 and STAT3 in transformed B cells. Hence, incurability with conventional chemotherapy and the profound immunodeficiency associated with CLL could be linked to expression and activity of PPARa.
The results in this paper suggest that MK886 has previously unrecognized potential as a therapeutic agent for aggressive forms of CLL. At concentrations in the 5-10 mM range, MK886 kills resting CLL cells (Figure 4a ) and causes proliferating cells to undergo immunogenic death (Figure 4 ). These concentrations of MK886 can be achieved in vivo and cause CLL cells to be cleared from xenografted immunodeficient mice ( Figure 5 ). Given its prior use in humans, 10 these findings suggest MK886 is worthy of further exploration as a new treatment for CLL.
The mechanism by which MK886 is acting to clear CLL cells in vivo is not clear. Most of the CLL cells that are present in xenografted NOD-SCIDg c null mice are not proliferating (o3% Ki67 þ cells 14 ) so that much of the effect may be related to direct toxicity of MK886 on non-proliferating cells (Figure 4a ). The possibility that its antitumor effects are due to inhibition of leukotriene production seems unlikely as two other leukotriene inhibitors AA861 and AM103 do not share this activity (Figure 5d ). MK886 has been used in many studies as a PPARa-antagonist. 11 However, its mechanism of action may extend beyond a specific nuclear receptor as it is thought to prevent the conformational change in PPARa required to dismiss corepressors and recruit coactivators for gene transcription. 11 Structural features of this shift are common to members of the nuclear receptor superfamily 8 and it is possible that MK886 blocks multiple nuclear receptors to account for its antitumor activity. Regardless, together with previous findings of increased tumor clearance in PPARA À / À mice, 36 our observations suggest that PPARa antagonists may be useful treatments for CLL and possibly other cancers.
